Loading...

HBM Holdings Limited

HBMHFPNK
Healthcare
Biotechnology
$1.60
$0.00(0.00%)

HBM Holdings Limited (HBMHF) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for HBM Holdings Limited (HBMHF), covering cash flow, earnings, and balance sheets.

Revenue Growth
-57.43%
57.43%
Operating Income Growth
-116.93%
116.93%
Net Income Growth
-87.81%
87.81%
Operating Cash Flow Growth
260.42%
260.42%
Operating Margin
-9.71%
9.71%
Gross Margin
85.29%
85.29%
Net Profit Margin
7.29%
7.29%
ROE
2.25%
2.25%
ROIC
-2.54%
2.54%

HBM Holdings Limited (HBMHF) Income Statement & Financial Overview

View the income breakdown for HBM Holdings Limited HBMHF across both annual and quarterly reports.

MetricQ4 2024Q2 2024Q4 2023Q3 2023
Revenue$14.40M$23.70M$48.56M$24.25M
Cost of Revenue$3.30M$1.19M$4.19M$1.006M
Gross Profit$11.10M$22.52M$44.37M$23.25M
Gross Profit Ratio$0.77$0.95$0.91$0.96
R&D Expenses$7.90M$13.10M$14.90M$8.35M
SG&A Expenses$6.68M$9.63M$12.14M$5.99M
Operating Expenses$14.59M$22.72M$27.04M$15.41M
Total Costs & Expenses$17.89M$23.91M$15.35M$16.41M
Interest Income$0.00$0.00$5.63M$2.05M
Interest Expense$0.00$0.00$1.53M$0.00
Depreciation & Amortization$1.60M$1.20M$2.18M$813000.00
EBITDA-$1.89M$992000.00$23.51M$9.17M
EBITDA Ratio-$0.13$0.04$0.48$0.38
Operating Income-$3.49M-$205000.00$17.32M$8.65M
Operating Income Ratio-$0.24-$0.009$0.36$0.36
Other Income/Expenses (Net)$5.50M$1.93M$2.48M$985500.00
Income Before Tax$2.02M$1.72M$19.80M$9.89M
Income Before Tax Ratio$0.14$0.07$0.41$0.41
Income Tax Expense$670000.00$327000.00-$70076.00$35000.00
Net Income$1.35M$1.42M$19.90M$9.94M
Net Income Ratio$0.09$0.06$0.41$0.41
EPS$0.002$0.002$0.03$0.01
Diluted EPS$0.002$0.002$0.03$0.01
Weighted Avg Shares Outstanding$805.95M$739.36M$755.36M$755.36M
Weighted Avg Shares Outstanding (Diluted)$805.90M$739.010M$735.50M$735.50M

Financial performance has remained strong, with revenue growing from $24.25M in Q3 2023 to $14.40M in Q4 2024. Gross profit continued to perform well, with margins at 77% in the latest quarter. Operating income reached -$3.49M in Q4 2024, holding a steady -24% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$1.89M. Net income dropped to $1.35M, keeping EPS at $0.002. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;